Immix Biopharma Inc
IMMX
NASDAQ
Biotechnology
$10.97
USD
+0.05 (+0.46%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $781.21M
Volume 1.3M
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-39.92M
TTM
-72.6%
YoY
Operating Cash Flow
$-38.50M
TTM
-207.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 2.7 | 3.1 | 5.2 | 4.8 | 7.1 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 6.7 | 7.7 | 10.9 | 10.8 | 12.5 |
Operating Income | -6.7 | -7.7 | -10.9 | -10.8 | -12.5 |
EBITDA | -6.7 | -7.6 | -10.8 | -10.7 | -12.4 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 0.1 | 0.1 | 0.2 | 0.7 | 0.9 |
Income Before Income Taxes | -6.6 | -7.6 | -10.7 | -10.1 | -11.5 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -6.6 | -7.6 | -10.7 | -10.1 | -11.6 |
Consolidated Net Income / Loss | -6.6 | -7.6 | -10.7 | -10.1 | -11.6 |
Net Income Attributable to Common Shareholders | -6.6 | -7.6 | -10.7 | -10.0 | -11.6 |
Basic EPS | -$0.22 | -$0.24 | -$0.27 | -$0.18 | -$0.18 |
Diluted EPS | -$0.22 | -$0.24 | -$0.27 | -$0.18 | -$0.18 |
Basic Shares Outstanding | 30.0M | 31.9M | 40.3M | 55.4M | 63.8M |
Diluted Shares Outstanding | 30.0M | 31.9M | 40.3M | 55.4M | 63.8M |